ArticleInternational journal of technology assessment in health care2023
Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment.
Article in International journal of technology assessment in health care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Action Plan to Better Approximate Reality in Cost-Effectiveness Analyses.Applied health economics and health policy · 2026Article
- Regulatory and HTA framework for herbal medicines in Indonesia.Journal of pharmaceutical policy and practice · 2026Review
- Expert participation in the health technology assessment process: a scoping review.Revista brasileira de enfermagem · 2026Article
- Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands.International journal of technology assessment in health care · 2025Article
- Cost-effectiveness of robotic-assisted versus conventional total knee arthroplasty: an analysis from a middle income country.Acta orthopaedica · 2025Article
- Early health technology assessment: current and future perspectives from a health technology assessment agency.International journal of technology assessment in health care · 2025Article
- Connecting minds and catalyzing collaboration: the interest groups of health technology assessment international.International journal of technology assessment in health care · 2025Review
- Patient Engagement and Patient Experience Data in Regulatory Review and Health Technology Assessment: Where Are We Today?Therapeutic innovation & regulatory science · 2025Review
- Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews.International journal of technology assessment in health care · 2025Article
- Applications of artificial intelligence and the challenges in health technology assessment: a scoping review and framework with a focus on economic dimensions.Health economics review · 2025Review
- HTA responsiveness to today's challenges to health systems: a responsible innovation in health perspective.International journal of technology assessment in health care · 2025Article
- Ethical challenges for Health Technology Assessment (HTA) in the evolving evidence landscape.International journal of technology assessment in health care · 2024Review
- Unleashing the potential: the imperative of political support for health technology assessment in Iran.Health economics review · 2024Article
- An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report.International journal of technology assessment in health care · 2024Review
- Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report.International journal of technology assessment in health care · 2024Review
- Multidimensional Impact of Dupilumab on Chronic Rhinosinusitis with Nasal Polyps: A Complete Health Technology Assessment of Clinical, Economic, and Non-Clinical Domains.Journal of personalized medicine · 2024Article
- New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.NPJ precision oncology · 2024Review
- Holistic Human-Serving Digitization of Health Care Needs Integrated Automated System-Level Assessment Tools.Journal of medical Internet research · 2023Article
- Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment.International journal of technology assessment in health care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lifecycle considerations have always been part of health technology assessment (HTA). However, the concept of taking a fuller, more holistic "lifecycle approach" is gaining interest in the HTA community. The 2022 HTAi Global Policy Forum (GPF) discussed how adopting a lifecycle approach could promote stakeholder engagement and robust evidence generation, and whether it could enhance information sharing and transparency across stakeholder groups. This article summarizes the discussions held at the 2022 HTAi GPF and subsequent HTAi Annual Meeting panel session that debated some of the key challenges and opportunities, with particular focus on the pre- and postmarket and disinvestment phase activities. Core themes and recommendations identified that collaboration and patient involvement are happening but still needs to be strengthened, and moving to disease-based approaches may help, although individual contexts still need to be considered. Appropriately developed and mandated core outcome sets may help with information sharing and efficiency in all lifecycle activities. Further, methods for the appropriate use of big data and digital data collection should be developed and driven by the HTA community. The value of lifecycle activities should be reviewed; in particular, scientific advice appears valuable, but the magnitude of effect is somewhat unknown due to the challenges around the confidential nature of these activities. Not all lifecycle activities can be conducted for every technology, and while there is a move away from disinvestment phase activities, more structured prioritization criteria are required. This article ends with suggested next steps to bring forward some of the priority recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.